Differentiation of diabetes by pathophysiology, natural history, and prognosis

Diabetes

Volumn 66, Issue 2, 2017, Pages 241-255

  Skyler, Jay S ^a   Bakris, George L ^b   Bonifacio, Ezio ^c   Darsow, Tamara ^d   Eckel, Robert H ^e   Groop, Leif ^f   Groop, Per Henrik ^g,h,i   Handelsman, Yehuda ^j   Insel, Richard A ^k   Mathieu, Chantal ^l   McElvaine, Allison T ^d   Palmer, Jerry P ^m   Pugliese, Alberto ^a   Schatz, Desmond A ⁿ   Sosenko, Jay M ^a   Wilding, John P H ^o   Ratner, Robert E ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d AMERICAN DIABETES ASSOCIATION   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f LUND UNIVERSITY   (Sweden)

^g UNIVERSITY OF HELSINKI   (Finland)

^h FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

ⁱ BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^j Metabolic Institute of America   (United States)

^k JDRF   (United States)

^l UNIVERSITY OF LEUVEN   (Belgium)

^m UNIVERSITY OF WASHINGTON   (United States)

ⁿ UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^o UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

AUTOIMMUNITY; BODY WEIGHT; CARDIOVASCULAR DISEASE; COMORBIDITY; DEMOGRAPHY; ENVIRONMENTAL FACTOR; GENETICS; GENOTYPE; HISTORY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; MEDICAL RESEARCH; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; DIABETIC COMPLICATION; DISEASE EXACERBATION; METABOLISM; RISK FACTOR;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; PHENOTYPE; PRECISION MEDICINE; PROGNOSIS; RISK FACTORS;

EID: 85011634413     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0806     Document Type: Review

References (176)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149
2. National Institute for Health and Care Excellence. NICE guidance [Internet]. Available from https://www.nice.org.uk/guidance/conditions-Anddiseases/diabetes-And-other-endocrinal-nutritional-And-metabolic-conditions/diabetes?unlid=957964380201659104345. Accessed 27 January 2016
3. Dietel M, Jöhrens K, Laffert MV, et al. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther 2015;22:417-430
4. Matveyenko AV, Butler PC. Relationship between beta-cell mass and diabetes onset. Diabetes Obes Metab 2008;10(Suppl. 4):23-31
5. Campbell-Thompson M, Fu A, Kaddis JS, et al. Insulitis and b-cell mass in the natural history of type 1 diabetes. Diabetes 2016;65:719-731
6. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. b-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005;90:493-500
7. Dabelea D, Mayer-Davis EJ, Saydah S, et al.; SEARCH for Diabetes in Youth Study. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014;311:1778-1786
8. International Diabetes Federation. IDF Diabetes Atlas, 7th edition [Internet], 2015. Available from http://diabetesatlas.org. Accessed 7 January 2016
9. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. U.S. Department of Health and Human Services, 2014
10. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am 2010;39:481-497
11. Livingstone SJ, Levin D, Looker HC, et al.; Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 2015;313:37-44
12. Stenström G, Gottsäter A, Bakhtadze E, Berger B, Sundkvist G. Latent autoimmune diabetes in adults: definition, prevalence, b-cell function, and treatment. Diabetes 2005;54(Suppl. 2):S68-S72
13. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000;23:1516-1526
14. Knip M, Veijola R, Virtanen SM, Hyöty H, Vaarala O, Akerblom HK. Environmental triggers and determinants of type 1 diabetes. Diabetes 2005;54 (Suppl. 2):S125-S136
15. Centers for Disease Control and Prevention. Age-Adjusted rates of diagnosed diabetes per 100 civilian, non-institutionalized population, by sex, United States, 1980-2014 [Internet]. Available from: http://www.cdc.gov/diabetes/statistics/prev/national/figbysex.htm. Accessed 19 November 2015
16. Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-Analysis. Int J Epidemiol 2011;40:804-818
17. Prasad RB, Groop L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes (Basel) 2015;6:87-123
18. Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 1996;45:1585-1593
19. Hämäläinen A-M, Knip M. Autoimmunity and familial risk of type 1 diabetes. Curr Diab Rep 2002;2:347-353
20. Hemminki K, Li X, Sundquist K, Sundquist J. Familial risks for type 2 diabetes in Sweden. Diabetes Care 2010;33:293-297
21. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008;4:200-213
22. Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. Diabetologia 1981;20:87-93
23. Srikanta S, Ganda OP, Eisenbarth GS, Soeldner JS. Islet-cell antibodies and beta-cell function in monozygotic triplets and twins initially discordant for type I diabetes mellitus. N Engl J Med 1983;308:322-325
24. Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T. Concordance for islet autoimmunity among monozygotic twins. N Engl J Med 2008;359:2849-2850
25. Rich SS. Mapping genes in diabetes. Genetic epidemiological perspective. Diabetes 1990;39:1315-1319
26. Aly TA, Ide A, Jahromi MM, et al. Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci USA 2006;103:14074-14079
27. Noble JA, Valdes AM, Varney MD, et al.; Type 1 Diabetes Genetics Consortium. HLA class I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium. Diabetes 2010;59:2972-2979
28. Hu X, Deutsch AJ, Lenz TL, et al. Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk. Nat Genet 2015;47:898-905
29. Cooper JD, Howson JMM, Smyth D, et al.; Type 1 Diabetes Genetics Consortium. Confirmation of novel type 1 diabetes risk loci in families. Diabetologia 2012;55:996-1000
30. Long SA, Cerosaletti K, Bollyky PL, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+CD25+ regulatory T-cells of type 1 diabetic subjects. Diabetes 2010;59:407-415
31. Long SA, Cerosaletti K, Wan JY, et al. An autoimmune-Associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells. Genes Immun 2011;12:116-125
32. Pugliese A, Zeller M, Fernandez A Jr., et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997;15: 293-297
33. Sosinowski T, Eisenbarth GS. Type 1 diabetes: primary antigen/peptide/register/trimolecular complex. Immunol Res 2013;55:270-276
34. Colli ML, Moore F, Gurzov EN, Ortis F, Eizirik DL. MDA5 and PTPN2, two candidate genes for type 1 diabetes, modify pancreatic beta-cell responses to the viral by-product double-stranded RNA. Hum Mol Genet 2010; 19:135-146
35. Marroqui L, Dos Santos RS, Fløyel T, et al. TYK2, a candidate gene for type 1 diabetes, modulates apoptosis and the innate immune response in human pancreatic b-cells. Diabetes 2015;64:3808-3817
36. Fløyel T, Kaur S, Pociot F. Genes affecting b-cell function in type 1 diabetes. Curr Diab Rep 2015;15:97
37. Santin I, Eizirik DL. Candidate genes for type 1 diabetes modulate pancreatic islet inflammation and b-cell apoptosis. Diabetes Obes Metab 2013;15 (Suppl. 3):71-81
38. Törn C, Hadley D, Lee H-S, et al.; TEDDY Study Group. Role of type 1 diabetes-Associated SNPs on risk of autoantibody positivity in the TEDDY study. Diabetes 2015;64:1818-1829
39. Steck AK, Wong R, Wagner B, et al. Effects of non-HLA gene polymorphisms on development of islet autoimmunity and type 1 diabetes in a population with high-risk HLA-DR,DQ genotypes. Diabetes 2012;61:753-758
40. Stankov K, Benc D, Draskovic D. Genetic and epigenetic factors in etiology of diabetes mellitus type 1. Pediatrics 2013;132:1112-1122
41. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015;38:1964-1974
42. Redondo MJ, Muniz J, Rodriguez LM, et al. Association of TCF7L2 variation with single islet autoantibody expression in children with type 1 diabetes. BMJ Open Diabetes Res Care 2014;2:e000008
43. Basile KJ, Guy VC, Schwartz S, Grant SFA. Overlap of genetic susceptibility to type 1 diabetes, type 2 diabetes, and latent autoimmune diabetes in adults. Curr Diab Rep 2014;14:550
44. Oram RA, Patel K, Hill A, et al. A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care 2016;39:337-344
45. Morris AP, Voight BF, Teslovich TM, et al.; Wellcome Trust Case Control Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology Network-Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; DIAbetes Genetics Replication And Meta-Analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012;44:981-990
46. Scott RA, Lagou V, Welch RP, et al.; DIAbetes Genetics Replication and Meta-Analysis (DIAGRAM) Consortium. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 2012;44:991-1005
47. Gaulton KJ, Ferreira T, Lee Y, et al.; DIAbetes Genetics Replication And Meta-Analysis (DIAGRAM) Consortium. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet 2015;47:1415-1425
48. Travers ME, Mackay DJG, Dekker Nitert M, et al. Insights into the molecular mechanism for type 2 diabetes susceptibility at the KCNQ1 locus from temporal changes in imprinting status in human islets. Diabetes 2013;62: 987-992
49. Portha B, Chavey A, Movassat J. Early-life origins of type 2 diabetes: fetal programming of the beta-cell mass. Exp Diabetes Res 2011;2011:105076
50. Flannick J, Thorleifsson G, Beer NL, et al.; Go-T2D Consortium; T2D-GENES Consortium. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet 2014;46:357-363
51. Schneider DA, von Herrath MG. Potential viral pathogenic mechanism in human type 1 diabetes. Diabetologia 2014;57:2009-2018
52. Roivainen M, Klingel K. Virus infections and type 1 diabetes risk. Curr Diab Rep 2010;10:350-356
53. Giongo A, Gano KA, Crabb DB, et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J 2011;5:82-91
54. Norris JM, Barriga K, Klingensmith G, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 2003;290:1713-1720
55. Ziegler A-G, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1 diabetes-Associated autoantibodies. JAMA 2003;290:1721-1728
56. Hagopian WA, Lernmark A, Rewers MJ, et al. TEDDY-The Environmental Determinants of Diabetes in the Young: an observational clinical trial. Ann N Y Acad Sci 2006;1079:320-326
57. Tiberti C, Giordano C, Locatelli M, et al. Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. Diabetes 2008;57:1276-1283
58. Brooks-Worrell BM, Boyko EJ, Palmer JP. Impact of islet autoimmunity on the progressive b-cell functional decline in type 2 diabetes. Diabetes Care 2014; 37:3286-3293
59. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994;17:961-969
60. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-486
61. van der Zijl NJ, Goossens GH, Moors CCM, et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on b-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab 2011;96: 459-467
62. Araneta MRG, Kanaya AM, Hsu WC, et al. Optimum BMI cut points to screen Asian Americans for type 2 diabetes. Diabetes Care 2015;38:814-820
63. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes 1986; 35:990-998
64. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506-2514
65. McCaffery JM, Jablonski KA, Franks PW, et al.; Diabetes Prevention Program Research Group. TCF7L2 polymorphism, weight loss and proinsulin: insulin ratio in the diabetes prevention program. PLoS One 2011;6:e21518
66. Panunzi S, Carlsson L, De Gaetano A, et al. Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care 2016;39: 166-174
67. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. b-Cell deficit and increased b-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110
68. Laybutt DR, Kaneto H, Hasenkamp W, et al. Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to b-cell survival during chronic hyperglycemia. Diabetes 2002;51:413-423
69. Weir GC, Bonner-Weir S. Five stages of evolving b-cell dysfunction during progression to diabetes. Diabetes 2004;53(Suppl. 3):S16-S21
70. Vardi P, Crisa L, Jackson RA. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 1991;34:93-102
71. Chase HP, Voss MA, Butler-Simon N, Hoops S, O'Brien D, Dobersen MJ. Diagnosis of pre-type I diabetes. J Pediatr 1987;111:807-812
72. Srikanta S, Ganda OP, Rabizadeh A, Soeldner JS, Eisenbarth GS. Firstdegree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion. N Engl J Med 1985;313:461-464
73. Ginsberg-Fellner F, Witt ME, Franklin BH, et al. Triad of markers for identifying children at high risk of developing insulin-dependent diabetes mellitus. JAMA 1985;254:1469-1472
74. Sosenko JM, Skyler JS, Beam CA, et al.; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes 2013;62:4179-4183
75. Sosenko JM, Palmer JP, Rafkin LE, et al.; Diabetes Prevention Trial-Type 1 Study Group. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes Care 2010;33:620-625
76. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS; DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 2010;59:679-685
77. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
78. Greenbaum CJ, Beam CA, Boulware D, et al.; Type 1 Diabetes TrialNet Study Group. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012;61:2066-2073
79. Oram RA, Jones AG, Besser REJ, et al. The majority of patients with longduration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 2014;57:187-191
80. Rosenbloom AL, Hunt SS, Rosenbloom EK, Maclaren NK. Ten-year prognosis of impaired glucose tolerance in siblings of patients with insulin-dependent diabetes. Diabetes 1982;31:385-387
81. Tarn AC, Smith CP, Spencer KM, Bottazzo GF, Gale EA. Type I (insulin dependent) diabetes: a disease of slow clinical onset? Br Med J (Clin Res Ed) 1987;294:342-345
82. Beer SF, Heaton DA, Alberti KG, Pyke DA, Leslie RD. Impaired glucose tolerance precedes but does not predict insulin-dependent diabetes mellitus: a study of identical twins. Diabetologia 1990;33:497-502
83. Sosenko JM, Palmer JP, Greenbaum CJ, et al.; Diabetes Prevention Trial-Type 1 Study Group. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2007;30:38-42
84. Sosenko JM, Skyler JS, Krischer JP, et al.; Diabetes Prevention Trial-Type 1 Study Group. Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). Diabetes 2010;59:2386-2389
85. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al.; Diabetes Prevention Trial-Type 1 Study Group. Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009; 32:1603-1607
86. Sosenko JM, Krischer JP, Palmer JP, et al.; Diabetes Prevention Trial-Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibodypositive participants in the diabetes prevention trial-type 1. Diabetes Care 2008;31: 528-533
87. Sosenko JM, Skyler JS, Mahon J, et al.; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787
88. Basu A, Dalla Man C, Basu R, Toffolo G, Cobelli C, Rizza RA. Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism. Diabetes Care 2009;32:866-872
89. van Haeften TW, Pimenta W, Mitrakou A, et al. Relative conributions of beta-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism 2000;49:1318-1325
90. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984;74:1318-1328
91. Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (noninsulin-dependent) diabetes mellitus. Diabetologia 1988;31:355-360
92. American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl. 1):S52-S59
93. Phillips LS, Ratner RE, Buse JB, Kahn SE. We can change the natural history of type 2 diabetes. Diabetes Care 2014;37:2668-2676
94. Bergman M, Dankner R, Roth J, Narayan KMV. Are current diagnostic guidelines delaying early detection of dysglycemic states? Time for new approaches. Endocrine 2013;44:66-69
95. Phillips LS, Twombly JG. It's time to overcome clinical inertia. Ann Intern Med 2008;148:783-785
96. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med 2007;22:453-458
97. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013;36:3411-3417
98. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344: 1343-1350
99. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
100. Gong Q, Gregg EW, Wang J, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetesrelated microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia 2011;54:300-307
101. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243-2251
102. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014;2:474-480
103. Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care 2015;38:989-996
104. Vehik K, Lynch KF, Schatz DA, et al.; TEDDY Study Group. Reversion of b-cell autoimmunity changes risk of type 1 diabetes: TEDDY study. Diabetes Care 2016;39:1535-1542
105. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309: 2473-2479
106. Steck AK, Vehik K, Bonifacio E, et al.; TEDDY Study Group. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care 2015;38:808-813
107. Orban T, Sosenko JM, Cuthbertson D, et al.; Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32:2269-2274
108. Colman PG, Steele C, Couper JJ, et al. Islet autoimmunity in infants with a type I diabetic relative is common but is frequently restricted to one autoantibody. Diabetologia 2000;43:203-209
109. Ziegler A-G, Bonifacio E; BABYDIAB-BABYDIET Study Group. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 2012;55:1937-1943
110. Parikka V, Näntö-Salonen K, Saarinen M, et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 2012;55:1926-1936
111. Krischer JP, Lynch KF, Schatz DA, et al.; TEDDY Study Group. The 6 year incidence of diabetes-Associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 2015;58:980-987
112. Leslie RD, Palmer J, Schloot NC, Lernmark A. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 2016;59:13-20
113. Pearson ER. Personalized medicine in diabetes: the role of 'omics' and biomarkers. Diabet Med 2016;33:712-717
114. Shepherd M, Pearson ER, Houghton J, Salt G, Ellard S, Hattersley AT. No deterioration in glycemic control in HNF-1a maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 2003;26: 3191-3192
115. Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol 2011;67:471-476
116. Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CNA, Pearson ER. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes 2015;64:1786-1793
117. Connelly PJ, Smith N, Chadwick R, Exley AR, Shneerson JM, Pearson ER. Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance. Diabet Med 2016;33:371-375
118. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003;5:163-170
119. Brooks-Worrell BM, Palmer JP. Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients. Clin Exp Immunol 2013;171:164-170
120. Jones AG, McDonald TJ, Shields BM, et al.; PRIBA Study Group. Markers of b-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 2016;39:250-257
121. Ohki T, Isogawa A, Toda N, Tagawa K. Effectiveness of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for nonalcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors. Clin Drug Investig 2016;36:313-319
122. Wilding JPH, Woo V, Soler NG, et al.; Dapagliflozin 006 Study Group. Longterm efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012;156:405-415
123. Yeh H-C, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-Analysis. Ann Intern Med 2012;157: 336-347
124. Tamborlane WV, Beck RW, Bode BW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359: 1464-1476
125. Weyer C, Gottlieb A, Kim DD, et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care 2003;26:3074-3079
126. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 2004;21:1204-1212
127. Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006;29:2189-2195
128. Raju B, Arbelaez AM, Breckenridge SM, Cryer PE. Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments. J Clin Endocrinol Metab 2006;91:2087-2092
129. Riccardi G, Giacco R, Parillo M, et al. Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med 1999;16:228-232
130. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care 2005;28:1562-1567
131. Shimada A, Shigihara T, Okubo Y, Katsuki T, Yamada Y, Oikawa Y. Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes. Diabetes Metab Res Rev 2011;27:951-953
132. Yang Z, Zhou Z, Li X, Huang G, Lin J. Rosiglitazone preserves islet betacell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract 2009;83:54-60
133. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 2010;53:809-820
134. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual b-cell function. Diabetes Care 2011;34: 1463-1468
135. Crisci I, Aragona M, Politi KS, Daniele G, Del Prato S. GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. Acta Diabetol 2015; 52:1129-1133
136. Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigatorinitiated, double-blind, randomized, placebo-controlled trial. Endocr Pract 2013;19:19-28
137. Mudaliar S, Armstrong DA, Mavian AA, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care 2012;35:2198-2200
138. Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care 2016;39:532-538
139. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359: 1577-1589
140. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853
141. Twito O, Frankel M, Nabriski D. Impact of glucose level on morbidity and mortality in elderly with diabetes and pre-diabetes. World J Diabetes 2015;6: 345-351
142. Flynn C, Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol 2013;9:147-153
143. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014;37:2864-2883
144. Chachou A, Randoux C, Millart H, Chanard J, Gillery P. Influence of in vivo hemoglobin carbamylation on HbA1c measurements by various methods. Clin Chem Lab Med 2000;38:321-326
145. Chow E, Bernjak A, Williams S, et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 2014;63:1738-1747
146. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
147. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
148. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373:232-242
149. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373:2247-2257
150. Dormandy JA, Charbonnel B, Eckland DJA, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289
151. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
152. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
153. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322
154. Wilding JPH. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract 2014;68:682-691
155. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986
156. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514-1523
157. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 2014;37: 2843-2863
158. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med 1985;78: 785-794
159. Finne P, Reunanen A, Stenman S, Groop P-H, Grönhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294:1782-1787
160. Martin CL, Albers JW, Pop-Busui R; DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014;37:31-38
161. Wadén J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH; Finnish Diabetic Nephropathy Study Group. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 2009;58:2649-2655
162. Thorn LM, Forsblom C, Fagerudd J, Pettersson-Fernholm K, Kilpikari R, Groop PH; FinnDiane Study Group. Clustering of risk factors in parents of patients with type 1 diabetes and nephropathy. Diabetes Care 2007;30: 1162-1167
163. Sharma K, Karl B, Mathew AV, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 2013;24: 1901-1912
164. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415-1428
165. Fellström B, Holdaas H, Jardine AG, et al.; AURORA Study Group. Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin 2009;25:271-285
166. Wanner C, Krane V, März W, et al.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248
167. Simó R, Simó-Servat O, Hernández C. Is fenofibrate a reasonable treatment for diabetic microvascular disease? Curr Diab Rep 2015;15:24
168. Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebocontrolled trial. Lancet 2011;377:2181-2192
169. Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-2397
170. Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M; International Diabetic Nephopathy Study Group. The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005;54: 2164-2171
171. Kalaitzidis RG, Bakris GL. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens 2009;18:386-391
172. Weir MR, Bakris GL. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010;31:469-470
173. Glassock RJ. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010;31:466-467
174. Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care 2014;37:867-875
175. Serhiyenko VA, Serhiyenko AA. Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives? World J Diabetes 2015;6: 245-258
176. Storm, P, Rosengren A, Groop L. A novel fine-tuned classification of diabetes with prognostic value: steps towards precision medicine (Abstract). Diabetes 2016;65(Suppl. 1):A94